Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $6 to $3.
Read original at benzingaStocks · News reference
Aprea Therapeutics Announces ACESOT-1051 Enrollment Is Accelerating; Clinical Data Presentation Planned For Q4 2026
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 30, 2026, 12:03 PM
- Checked
- Jul 30, 2026, 12:02 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Aprea Therapeutics, Inc. (APRE)
Filed: 2026-08-12 AccNo: 0001104659-26-094542 Size: 6 MB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarAprea Therapeutics Q2 EPS $(0.07) Beats $(0.23) Estimate
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.23) by 69.57 percent. This is a 86.79 percent increase over losses of $(0.53) per share
Read original at benzinga